|
1
|
Bittoni MA, Focht BC, Clinton SK,
Buckworth J and Harris RE: Prospective evaluation of C-reactive
protein, smoking and lung cancer death in the Third National Health
and Nutrition Examination Survey. Int J Oncol. 47:1537–1544. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nawaz K and Webster RM: The non-small-cell
lung cancer drug market. Nat Rev Drug Discov. 15:229–230. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Di X, Jin X, Li R, Zhao M and Wang K:
CircRNAs and lung cancer: Biomarkers and master regulators. Life
Sci. 220:177–185. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Youlden DR, Cramb SM and Baade PD: The
international epidemiology of lung cancer: Geographical
distribution and secular trends. J Thorac Oncol. 3:819–831. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li LC and Kan LD: Traditional Chinese
medicine for pulmonary fibrosis therapy: Progress and future
prospects. J Ethnopharmacol. 198:45–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Efferth T, Li PC, Konkimalla VS and Kaina
B: From traditional Chinese medicine to rational cancer therapy.
Trends Mol Med. 13:353–361. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu D, Chen L, Zhao H, Vaziri ND, Ma SC
and Zhao YY: Small molecules from natural products targeting the
Wnt/β-catenin pathway as a therapeutic strategy. Biomed
Pharmacother. 117:1089902019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ghantous A, Sinjab A, Herceg Z and
Darwiche N: Parthenolide: From plant shoots to cancer roots. Drug
Discov Today. 18:894–905. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang S, Ong CN and Shen HM: Critical
roles of intracellular thiols and calcium in parthenolide-induced
apoptosis in human colorectal cancer cells. Cancer Lett.
208:143–153. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu YC, Kim SL, Park YR, Lee ST and Kim
SW: Parthenolide promotes apoptotic cell death and inhibits the
migration and invasion of SW620 cells. Intest Res. 15:174–181.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu JW, Cai MX, Xin Y, Wu QS, Ma J, Yang
P, Xie HY and Huang DS: Parthenolide induces proliferation
inhibition and apoptosis of pancreatic cancer cells in vitro. J Exp
Clin Cancer Res. 29:1082010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wyrębska A, Szymański J, Gach K, Piekielna
J, Koszuk J, Janecki T and Janecka A: Apoptosis-mediated cytotoxic
effects of parthenolide and the new synthetic analog MZ-6 on two
breast cancer cell lines. Mol Biol Rep. 40:1655–1663. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jafari N, Nazeri S and Enferadi ST:
Parthenolide reduces metastasis by inhibition of vimentin
expression and induces apoptosis by suppression elongation factor
α-1 expression. Phytomedicine. 41:67–73. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Talib WH and Al Kury LT: Parthenolide
inhibits tumor- promoting effects of nicotine in lung cancer by
inducing P53-dependent apoptosis and inhibiting VEGF expression.
Biomed Pharmacother. 107:1488–1495. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin M, Bi H, Yan Y, Huang W, Zhang G,
Zhang G, Tang S, Liu Y, Zhang L, Ma J and Zhang J: Parthenolide
suppresses non-small cell lung cancer GLC-82 cells growth via
B-Raf/MAPK/Erk pathway. Oncotarget. 8:23436–23447. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Regad T: Targeting RTK signaling pathways
in cancer. Cancers (Basel). 7:1758–1784. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Denduluri SK, Idowu O, Wang Z, Liao Z, Yan
Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L and Luu HH:
Insulin-like growth factor (IGF) signaling in tumorigenesis and the
development of cancer drug resistance. Genes Dis. 2:13–25. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Casa AJ, Dearth RK, Litzenburger BC, Lee
AV and Cui X: The type I insulin-like growth factor receptor
pathway: A key player in cancer therapeutic resistance. Front
Biosci. 13:3273–3287. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weroha SJ and Haluska P: The insulin-like
growth factor system in cancer. Endocrinol Metab Clin North Am.
41335–350. (vi)2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mayer IA and Arteaga CL: The PI3K/AKT
pathway as a target for cancer Treatment. Annu Rev Med. 67:11–28.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Farhan M, Wang H, Gaur U, Little PJ, Xu J
and Zheng W: FOXO signaling pathways as therapeutic targets in
cancer. Int J Biol Sci. 13:815–827. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Coomans de Brachène A and Demoulin JB:
FOXO transcription factors in cancer development and therapy. Cell
Mol Life Sci. 73:1159–1172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hornsveld M, Dansen TB, Derksen PW and
Burgering BMT: Re-evaluating the role of FOXOs in cancer. Semin
Cancer Biol. 50:90–100. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang J, Wen G, Sun L, Yuan W, Wang R,
Zeng Q, Zhang G and Yu B: Cryptotanshinone inhibits cellular
proliferation of human lung cancer cells through downregulation of
IGF-1R/PI3K/Akt signaling pathway. Oncol Rep. 40:2926–2934.
2018.PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakabayashi H and Shimizu K: Involvement
of Akt/NF-κB pathway in antitumor effects of parthenolide on
glioblastoma cells in vitro and in vivo. BMC Cancer. 12:4532012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jakobsen JN and Sørensen JB: Clinical
impact of ki-67 labeling index in non-small cell lung cancer. Lung
Cancer. 79:1–7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Altorki NK, Markowitz GJ, Gao D, Port JL,
Saxena A, Stiles B, McGraw T and Mittal V: The lung
microenvironment: An important regulator of tumour growth and
metastasis. Nat Rev Cancer. 19:9–31. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jeyamohan S, Moorthy RK, Kannan MK and
Arockiam AJV: Parthenolide induces apoptosis and autophagy through
the suppression of PI3K/Akt signaling pathway in cervical cancer.
Biotechnol Lett. 38:1251–1260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu HJ, Jung JY, Jeong JH, Cho SD and Lee
JS: Induction of apoptosis by parthenolide in human oral cancer
cell lines and tumor xenografts. Oral Oncol. 51:602–609. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Stoimenov I and Helleday T: PCNA on the
crossroad of cancer. Biochem Soc Trans. 37:7(Pt 3). 605–613. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Juríková M, Danihel L, Polák Š and Varga
I: Ki67, PCNA, and MCM proteins: Markers of proliferation in the
diagnosis of breast cancer. Acta Histochem. 118:544–552. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peled N, Wynes MW, Ikeda N, Ohira T,
Yoshida K, Qian J, Ilouze M, Brenner R, Kato Y, Mascaux C and
Hirsch FR: Insulin-like growth factor-1 receptor (IGF-1R) as a
biomarker for resistance to the tyrosine kinase inhibitor gefitinib
in non-small cell lung cancer. Cell Oncol (Dordr). 36:277–288.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Singh P, Alex JM and Bast F: Insulin
receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R)
signaling systems: Novel treatment strategies for cancer. Med
Oncol. 31:8052014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gong Y, Yao E, Shen R, Goel A, Arcila M,
Teruya-Feldstein J, Zakowski MF, Frankel S, Peifer M, Thomas RK, et
al: High expression levels of total IGF-1R and sensitivity of NSCLC
cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One.
4:e72732009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang J, Nie J, Ma X, Wei Y, Peng Y and Wei
X: Targeting PI3K in cancer: Mechanisms and advances in clinical
trials. Mol Cancer. 18:262019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tzivion G, Dobson M and Ramakrishnan G:
FoxO transcription factors; Regulation by AKT and 14-3-3 proteins.
Biochim Biophys Acta. 1813:1938–1945. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Piperigkou Z, Manou D, Karamanou K and
Theocharis AD: Strategies to target matrix metalloproteinases as
therapeutic approach in cancer. Methods Mol Biol. 1731:325–348.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cathcart J, Pulkoski-Gross A and Cao J:
Targeting matrix metalloproteinases in cancer: Bringing new life to
old ideas. Genes Dis. 2:26–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu P, He J, Liu S, Wang M, Pan B and Zhang
W: β2-adrenergic receptor activation promotes the proliferation of
A549 lung cancer cells via the ERK1/2/CREB pathway. Oncol Rep.
36:1757–1763. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yao X, Jiang W, Yu D and Yan Z: Luteolin
inhibits proliferation and induces apoptosis of human melanoma
cells in vivo and in vitro by suppressing MMP-2 and MMP-9 through
the PI3K/AKT pathway. Food Funct. 10:703–712. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gao Y, Guan Z, Chen J, Xie H, Yang Z, Fan
J, Wang X and Li L: CXCL5/CXCR2 axis promotes bladder cancer cell
migration and invasion by activating PI3K/AKT-induced upregulation
of MMP2/MMP9. Int J Oncol. 47:690–700. 2015. View Article : Google Scholar : PubMed/NCBI
|
